CY1108799T1 - Αντισωμα αντι- ccr5 - Google Patents
Αντισωμα αντι- ccr5Info
- Publication number
- CY1108799T1 CY1108799T1 CY20091100160T CY091100160T CY1108799T1 CY 1108799 T1 CY1108799 T1 CY 1108799T1 CY 20091100160 T CY20091100160 T CY 20091100160T CY 091100160 T CY091100160 T CY 091100160T CY 1108799 T1 CY1108799 T1 CY 1108799T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ccr5
- atcc deposit
- deposit designation
- plasmid designated
- designation pta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Η εφεύρεση κατευθύνεται προς ένα αντίσωμα anti-CCR5 που περιλαμβάνει (i) δύο ελαφρές αλυσίδες, όπου κάθε ελαφρή αλυσίδα περιλαμβάνει το προϊόν έκφρασης ενός πλασμιδίου που συμβολίζεται με pVK: HuPRO140-VK, Αριθμός Κατάθεσης ATCC No. ΡΤΑ-4097, και (ii) δύο βαριές αλυσίδες, όπου κάθε βαριά αλυσίδα περιλαμβάνει είτε το προϊόν έκφρασης ενός πλασμιδίου που συμβολίζεται με pVgl: HuPRO140 HG2-VH, Αριθμός Κατάθεσης ATCC No. ΡΤΑ-4098 ή ενός πλασμιδίου που συμβολίζεται με pVgl: HuPRO140 (mut B+D+I)-VH Αριθμός Κατάθεσης ATCC No. PTA-4099, ή ένα κλάσμα αυτού, που συνδέεται με το CCR5 στην επιφάνεια ενός ανθρώπινου κυττάρου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8112802A | 2002-02-22 | 2002-02-22 | |
EP03713632A EP1478738B1 (en) | 2002-02-22 | 2003-02-21 | Anti-ccr5 antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108799T1 true CY1108799T1 (el) | 2014-04-09 |
Family
ID=27765254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100160T CY1108799T1 (el) | 2002-02-22 | 2009-02-12 | Αντισωμα αντι- ccr5 |
Country Status (20)
Country | Link |
---|---|
EP (2) | EP2058006A1 (el) |
JP (1) | JP2006508631A (el) |
KR (1) | KR20050004784A (el) |
CN (1) | CN1780907B (el) |
AT (1) | ATE414142T1 (el) |
AU (1) | AU2003217674C1 (el) |
CA (1) | CA2476901C (el) |
CY (1) | CY1108799T1 (el) |
DE (1) | DE60324664D1 (el) |
DK (1) | DK1478738T3 (el) |
ES (1) | ES2316740T3 (el) |
HK (1) | HK1072272A1 (el) |
IL (1) | IL163655A0 (el) |
MX (1) | MXPA04008153A (el) |
NO (1) | NO20043971L (el) |
NZ (2) | NZ534947A (el) |
PT (1) | PT1478738E (el) |
RU (1) | RU2322454C2 (el) |
WO (1) | WO2003072766A1 (el) |
ZA (1) | ZA200406765B (el) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7858298B1 (en) | 1996-04-01 | 2010-12-28 | Progenics Pharmaceuticals Inc. | Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists |
US7138119B2 (en) | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
US7060273B2 (en) | 2001-04-06 | 2006-06-13 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
MX2008000984A (es) * | 2005-07-22 | 2008-04-04 | Progenics Pharm Inc | Metodos para reducir la carga viral en pacientes infectados con vih-1. |
TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
JP2010500984A (ja) | 2006-08-17 | 2010-01-14 | エフ.ホフマン−ラ ロシュ アーゲー | Ccr5に対する抗体と抗膜融合ペプチドとの抱合体 |
KR20090052358A (ko) | 2006-09-29 | 2009-05-25 | 에프. 호프만-라 로슈 아게 | Ccr5 에 대한 항체 및 이의 용도 |
CL2008000707A1 (es) | 2007-03-13 | 2008-09-22 | Hoffmann La Roche | Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion. |
EP2331133A4 (en) * | 2008-09-05 | 2012-09-12 | Univ Duke | ANTILIPID ANTIBODIES |
WO2011109365A2 (en) * | 2010-03-01 | 2011-09-09 | Progenics Pharmaceuticals, Inc. | Concentrated protein formulations and uses thereof |
EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
CA2988650A1 (en) | 2015-06-23 | 2016-12-29 | Cytodyn Inc. | Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions |
WO2017087547A1 (en) * | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
KR20220127859A (ko) * | 2020-01-13 | 2022-09-20 | 사이토딘 인크. | Ccr5 양성 전이성 암 치료를 위한 ccr5 결합제 |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6528625B1 (en) * | 1996-10-28 | 2003-03-04 | Millennium Pharmaceuticals, Inc. | Anti-CCR5 antibodies and kits comprising same |
US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
CA2355607A1 (en) * | 1998-12-16 | 2000-06-22 | Progenics Pharmaceuticals, Inc. | Anti-ccr5 antibody |
JP3459386B2 (ja) | 1999-10-15 | 2003-10-20 | Smc株式会社 | 可逆式取付機構を有する流体圧機器 |
-
2003
- 2003-02-21 DE DE60324664T patent/DE60324664D1/de not_active Expired - Lifetime
- 2003-02-21 CA CA2476901A patent/CA2476901C/en not_active Expired - Lifetime
- 2003-02-21 NZ NZ534947A patent/NZ534947A/en not_active IP Right Cessation
- 2003-02-21 DK DK03713632T patent/DK1478738T3/da active
- 2003-02-21 CN CN038090600A patent/CN1780907B/zh not_active Expired - Lifetime
- 2003-02-21 NZ NZ561465A patent/NZ561465A/en not_active IP Right Cessation
- 2003-02-21 IL IL16365503A patent/IL163655A0/xx unknown
- 2003-02-21 WO PCT/US2003/005500 patent/WO2003072766A1/en active Application Filing
- 2003-02-21 ES ES03713632T patent/ES2316740T3/es not_active Expired - Lifetime
- 2003-02-21 RU RU2004128252/13A patent/RU2322454C2/ru not_active IP Right Cessation
- 2003-02-21 MX MXPA04008153A patent/MXPA04008153A/es active IP Right Grant
- 2003-02-21 AU AU2003217674A patent/AU2003217674C1/en not_active Expired
- 2003-02-21 PT PT03713632T patent/PT1478738E/pt unknown
- 2003-02-21 EP EP08168669A patent/EP2058006A1/en not_active Withdrawn
- 2003-02-21 JP JP2003571454A patent/JP2006508631A/ja active Pending
- 2003-02-21 AT AT03713632T patent/ATE414142T1/de not_active IP Right Cessation
- 2003-02-21 KR KR10-2004-7013080A patent/KR20050004784A/ko not_active Application Discontinuation
- 2003-02-21 EP EP03713632A patent/EP1478738B1/en not_active Expired - Lifetime
-
2004
- 2004-08-25 ZA ZA200406765A patent/ZA200406765B/xx unknown
- 2004-09-22 NO NO20043971A patent/NO20043971L/no not_active Application Discontinuation
-
2005
- 2005-05-04 HK HK05103778.7A patent/HK1072272A1/xx not_active IP Right Cessation
-
2009
- 2009-02-12 CY CY20091100160T patent/CY1108799T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1478738A1 (en) | 2004-11-24 |
AU2003217674A1 (en) | 2003-09-09 |
EP2058006A1 (en) | 2009-05-13 |
DK1478738T3 (da) | 2009-03-09 |
CA2476901A1 (en) | 2003-09-04 |
IL163655A0 (en) | 2005-12-18 |
CA2476901C (en) | 2012-10-09 |
JP2006508631A (ja) | 2006-03-16 |
CN1780907A (zh) | 2006-05-31 |
EP1478738A4 (en) | 2006-05-31 |
HK1072272A1 (en) | 2005-08-19 |
WO2003072766A1 (en) | 2003-09-04 |
EP1478738B1 (en) | 2008-11-12 |
ES2316740T3 (es) | 2009-04-16 |
PT1478738E (pt) | 2009-02-16 |
NO20043971L (no) | 2004-11-16 |
ATE414142T1 (de) | 2008-11-15 |
MXPA04008153A (es) | 2005-07-05 |
AU2003217674C1 (en) | 2009-03-26 |
KR20050004784A (ko) | 2005-01-12 |
CN1780907B (zh) | 2011-06-15 |
NZ561465A (en) | 2009-04-30 |
AU2003217674B2 (en) | 2008-10-30 |
DE60324664D1 (de) | 2008-12-24 |
RU2004128252A (ru) | 2005-04-10 |
NZ534947A (en) | 2008-03-28 |
ZA200406765B (en) | 2006-06-28 |
RU2322454C2 (ru) | 2008-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108799T1 (el) | Αντισωμα αντι- ccr5 | |
AR075790A2 (es) | Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural) | |
LU92710I2 (fr) | Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza) | |
CY1110689T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια | |
CY1115730T1 (el) | Θεραπευτικοι επιτοποι και χρησεις αυτων | |
PT778891E (pt) | Anticorpo monoclonal recombinante anti-rhesus d (d7c2) | |
DK3572508T1 (da) | Hybrid-antistoffer indeholdende tunge kæder med humane VDJ områder og tungkæde konstante områder fra mus og lette kæder med humane VJ områder og letkæde konstante områder fra mus. | |
BR0315161A (pt) | Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição | |
ATE187494T1 (de) | Multivalente einkettige antikörper | |
RS54450B1 (en) | ANTIGEN-BINDING MOLECULES WITH INCREASED BINDING AFFINITY FOR FC RECEPTOR AND EFFECTOR FUNCTION | |
CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
WO2005003171A3 (en) | Modified antibody fragments | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
ATE479710T1 (de) | Bispezifische antikörper | |
IN2009KN02655A (el) | ||
NZ607711A (en) | Antibodies directed to her-3 and uses thereof | |
EP2267034A3 (en) | Gold-binding protein and use thereof | |
FI960567A (fi) | Monoklonaalinen vasta-aine, joka indusoi apoptoosin | |
DE69409225D1 (de) | Verbindungen für zielrichtung | |
AU628948B2 (en) | Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof | |
FR2841905B1 (fr) | Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications | |
WO2004050849A3 (en) | Recombinant immunotoxin and use in treating tumors | |
WO2004029214A8 (en) | Lfa-1 alpha subunit antibodies and methods of use | |
CY1117275T1 (el) | Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους | |
TH83706B (th) | แอนติ-5t4 แอนติบอดีที่ถูกฮิวมาไนซ์และคอนจูเกตของแอนติ-5t4 แอนติบอดี/คาลิซีอะไมซิน |